Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

478 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models.
La Monica S, Vacondio F, Eltayeb K, Lodola A, Volta F, Viglioli M, Ferlenghi F, Galvani F, Galetti M, Bonelli M, Fumarola C, Cavazzoni A, Flammini L, Verzè M, Minari R, Petronini PG, Tiseo M, Mor M, Alfieri R. La Monica S, et al. Among authors: mor m. Sci Rep. 2024 Mar 18;14(1):6491. doi: 10.1038/s41598-024-57028-8. Sci Rep. 2024. PMID: 38499619 Free PMC article.
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines.
Galetti M, Alfieri RR, Cavazzoni A, La Monica S, Bonelli M, Fumarola C, Mozzoni P, De Palma G, Andreoli R, Mutti A, Mor M, Tiseo M, Ardizzoni A, Petronini PG. Galetti M, et al. Among authors: mor m. Biochem Pharmacol. 2010 Jul 15;80(2):179-87. doi: 10.1016/j.bcp.2010.03.033. Epub 2010 Apr 2. Biochem Pharmacol. 2010. PMID: 20363215
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines.
Alfieri RR, Galetti M, Tramonti S, Andreoli R, Mozzoni P, Cavazzoni A, Bonelli M, Fumarola C, La Monica S, Galvani E, De Palma G, Mutti A, Mor M, Tiseo M, Mari E, Ardizzoni A, Petronini PG. Alfieri RR, et al. Among authors: mor m. Mol Cancer. 2011 Nov 23;10:143. doi: 10.1186/1476-4598-10-143. Mol Cancer. 2011. PMID: 22111840 Free PMC article.
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.
Galvani E, Alfieri R, Giovannetti E, Cavazzoni A, La Monica S, Galetti M, Fumarola C, Bonelli M, Mor M, Tiseo M, Peters GJ, Petronini PG, Ardizzoni A. Galvani E, et al. Among authors: mor m. Curr Pharm Des. 2013;19(5):818-32. Curr Pharm Des. 2013. PMID: 22973953 Review.
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines.
Fumarola C, Bozza N, Castelli R, Ferlenghi F, Marseglia G, Lodola A, Bonelli M, La Monica S, Cretella D, Alfieri R, Minari R, Galetti M, Tiseo M, Ardizzoni A, Mor M, Petronini PG. Fumarola C, et al. Among authors: mor m. Front Oncol. 2019 Mar 26;9:179. doi: 10.3389/fonc.2019.00179. eCollection 2019. Front Oncol. 2019. PMID: 30972293 Free PMC article.
478 results